Giancarlo Serra

Summary

Affiliation: University of Cagliari
Country: Italy

Publications

  1. ncbi Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, 09124 Cagliari, Italy
    Proc Natl Acad Sci U S A 99:3081-6. 2002
  2. ncbi Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, SS 554 Bivio Sestu, 09042 Cagliari, Italy
    Proc Natl Acad Sci U S A 103:8475-80. 2006
  3. ncbi Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis
    Patrizia Farci
    Dipartimento di Scienze Mediche, Universita di Cagliari, SS 554 Bivio Sestu, 09042 Cagliari, Italy
    Gastroenterology 126:1740-9. 2004
  4. ncbi Delta hepatitis: an update
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, SS 554, Bivio Sestu, 09042 Monserrato, Cagliari, Italy
    J Hepatol 39:S212-9. 2003
  5. ncbi Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359-362]
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, Via San Giorgio 12, 09124 Cagliari, Italy
    J Hepatol 36:582-5. 2002
  6. ncbi Hepatitis C virus. The importance of viral heterogeneity
    P Farci
    Department of Medical Sciences, University of Cagliari, Cagliari, Italy
    Clin Liver Dis 5:895-916. 2001
  7. ncbi Clinical significance of hepatitis C virus genotypes and quasispecies
    P Farci
    Department of Medical Sciences, University of Cagliari, Italy
    Semin Liver Dis 20:103-26. 2000
  8. ncbi The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
    P Farci
    Department of Medical Sciences, University of Cagliari, Via San Giorgio 12, 09124 Cagliari, Italy
    Science 288:339-44. 2000
  9. ncbi Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee
    P Farci
    Department of Internal Medicine, University of Cagliari, 09124 Cagliari, Italy
    J Infect Dis 179:1007-11. 1999
  10. ncbi Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin
    Cristiana Cauli
    Department of Medical Sciences, University of Cagliari, Italy
    Haematologica 91:ECR26. 2006

Collaborators

Detail Information

Publications20

  1. ncbi Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, 09124 Cagliari, Italy
    Proc Natl Acad Sci U S A 99:3081-6. 2002
    ....
  2. ncbi Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, SS 554 Bivio Sestu, 09042 Cagliari, Italy
    Proc Natl Acad Sci U S A 103:8475-80. 2006
    ..The sequences reported in this paper have been deposited in the GenBank database (accession nos. DQ 504441-DQ 507112)...
  3. ncbi Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis
    Patrizia Farci
    Dipartimento di Scienze Mediche, Universita di Cagliari, SS 554 Bivio Sestu, 09042 Cagliari, Italy
    Gastroenterology 126:1740-9. 2004
    ..Little is known about the long-term effects of interferon alpha on clinical outcome and survival of patients with chronic hepatitis D...
  4. ncbi Delta hepatitis: an update
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, SS 554, Bivio Sestu, 09042 Monserrato, Cagliari, Italy
    J Hepatol 39:S212-9. 2003
  5. ncbi Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359-362]
    Patrizia Farci
    Department of Medical Sciences, University of Cagliari, Via San Giorgio 12, 09124 Cagliari, Italy
    J Hepatol 36:582-5. 2002
  6. ncbi Hepatitis C virus. The importance of viral heterogeneity
    P Farci
    Department of Medical Sciences, University of Cagliari, Cagliari, Italy
    Clin Liver Dis 5:895-916. 2001
    ..Until such studies are performed, most ideas of viral clearance mechanisms remain hypothetical, and the immunologic basis of HCV clearance will continue to be inferred from associations rather than from causal relationships...
  7. ncbi Clinical significance of hepatitis C virus genotypes and quasispecies
    P Farci
    Department of Medical Sciences, University of Cagliari, Italy
    Semin Liver Dis 20:103-26. 2000
    ..This article reviews the state of the art on the biologic and clinical implications of the genetic variability of HCV...
  8. ncbi The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
    P Farci
    Department of Medical Sciences, University of Cagliari, Via San Giorgio 12, 09124 Cagliari, Italy
    Science 288:339-44. 2000
    ..These data indicate that the evolutionary dynamics of the HCV quasispecies during the acute phase of hepatitis C predict whether the infection will resolve or become chronic...
  9. ncbi Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee
    P Farci
    Department of Internal Medicine, University of Cagliari, 09124 Cagliari, Italy
    J Infect Dis 179:1007-11. 1999
    ....
  10. ncbi Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin
    Cristiana Cauli
    Department of Medical Sciences, University of Cagliari, Italy
    Haematologica 91:ECR26. 2006
    ..Our study demonstrates that in patients without preexisting immunological abnormalities Peg-IFN can de novo induce autoimmune complications that, albeit rarely, may be life-threatening...
  11. ncbi Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy
    Mauro G Carta
    Department of Public Health, University of Cagliari, Italy
    Clin Pract Epidemiol Ment Health 3:22. 2007
    ..This study was aimed at elucidating whether CHC is associated with specific anxiety or mood disorders independently of confounding factors...
  12. ncbi T lymphocyte subsets and viral infections in Sardinian parenteral drug abusers: relationship to HIV infection
    P Farci
    Department of Internal Medicine, University of Cagliari, Italy
    J Med Virol 27:81-6. 1989
    ..Our data confirm that HIV infection is the major cause of low T helper cells and reversed T helper/suppressor ratio in parenteral drug abusers.(ABSTRACT TRUNCATED AT 250 WORDS)..
  13. ncbi In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells
    Akito Sakai
    Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8009, USA
    J Virol 81:7208-19. 2007
    ..Subsequently, however, mutations emerged repeatedly in both animals. Overall, our results indicate that disease severity and outcome of acute HCV infection depend primarily on the host response...
  14. ncbi Treatment of chronic hepatitis D: New advances, old challenges
    Patrizia Farci
    Hepatology 44:536-9. 2006
  15. ncbi Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
    Cinzia Balestrieri
    Blood 107:3409-10. 2006
  16. ncbi Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C
    Daniele Prati
    Ospedale A Manzoni, Lecco and IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
    J Hepatol 44:679-85. 2006
    ..To clarify the role and interactions of viral and host factors in inducing liver cell injury, we examined the associations of several virological and metabolic variables with serum alanine aminotransferase levels...
  17. ncbi Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    Gastroenterology 127:1724-32. 2004
    ....
  18. ncbi Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  19. ncbi HCV-associated lymphomas
    Massimo Fiorilli
    Department of Clinical Medicine, University of Rome La Sapienza, Viale dell Universita, 37, 00185 Rome, Italy
    Rev Clin Exp Hematol 7:406-23. 2003
    ..The recent demonstration that splenic B cell lymphomas associated with HCV-infection may regress after successful antiviral therapy confirms a role for this virus in B-cell lymphomagenesis...
  20. ncbi Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...